HSCS Stock Price, Heart Test Laboratories, . Quote, Chart

Market Summary

USD0.09-0.01

Delayedas of 30 Apr 2024, 03:06 pm

-10.00%

HSCS Stock Price

View Fullscreen

HSCS RSI Chart

HSCS Valuation

Market Cap

6.6M

Price/Earnings (Trailing)

-1.03

Price/Sales (Trailing)

319.03

Price/Free Cashflow

-1.02

HSCS Price/Sales (Trailing)

HSCS Profitability

Operating Margin

66.71%

Return on Equity

-74.03%

Return on Assets

-59.18%

Free Cashflow Yield

-97.9%

HSCS Fundamentals

HSCS Revenue

Revenue (TTM)

20.6K

Rev. Growth (Yr)

653.85%

Rev. Growth (Qtr)

276.92%

HSCS Earnings

Earnings (TTM)

-6.4M

Earnings Growth (Yr)

-22.48%

Earnings Growth (Qtr)

5.98%

Breaking Down HSCS Revenue

52 Week Range

0.10

(Low)(High)

Last 30 days

-16.7%

Last 90 days

-28.6%

How does HSCS drawdown profile look like?

HSCS Financial Health

Current Ratio

5.09

HSCS Investor Care

Shares Dilution (1Y)

789.36%

Diluted EPS (TTM)

-0.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	20.6K	0	0	0
2023	9.3K	5.2K	0	5.8K
2022	17.2K	14.4K	10.1K	10.1K
2021	0	25.6K	22.8K	20.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Which funds bought or sold HSCS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 26, 2024	CULTIVAR CAPITAL, INC.	unchanged	-	-2,705	5,845	-%
Apr 23, 2024	Accurate Wealth Management, LLC	unchanged	-	-855	2,042	-%
Apr 18, 2024	CHAPIN DAVIS, INC.	unchanged	-	-811	1,754	-%
Mar 11, 2024	VANGUARD GROUP INC	new	-	30,028	30,028	-%
Feb 26, 2024	Virtu Financial LLC	new	-	2,000	2,000	-%
Feb 26, 2024	Virtu Financial LLC	added	896	33,000	44,000	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-3.00	-	-%
Feb 14, 2024	CLEAR STREET LLC	unchanged	-	-	13,000	-%
Feb 14, 2024	AE Wealth Management LLC	added	7.18	-19,327	10,326	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	new	-	5,273	5,273	-%

Are Funds Buying or Selling HSCS?

Are funds buying HSCS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HSCS

No. of Funds

Unveiling Heart Test Laboratories, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Dec 11, 2023	matthews holdings southwest, inc.	8.1%	5,241,758	SC 13G
Nov 27, 2023	icahn school of medicine at mount sinai	9.9%	4,854,853	SC 13G

Recent SEC filings of Heart Test Laboratories, Inc.

View All Filings

Date Filed	Form Type	Document
Mar 18, 2024	424B3	Prospectus Filed
Mar 14, 2024	8-K	Current Report
Mar 14, 2024	10-Q	Quarterly Report
Mar 13, 2024	EFFECT	EFFECT
Mar 12, 2024	CORRESP	CORRESP
Mar 11, 2024	UPLOAD	UPLOAD
Mar 05, 2024	S-1	Initial Public Offering
Feb 26, 2024	S-8	Employee Benefits Plan
Feb 15, 2024	8-K	Current Report
Jan 31, 2024	8-K	Current Report

Peers (Alternatives to Heart Test Laboratories, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.1B	40.1B	-5.62%	-2.90%	32.52	4.64	-8.12%	-17.45%
BDX	67.4B	19.5B	-5.66%	-11.68%	53.7	3.46	4.02%	-22.04%
ALGN	22.9B	3.9B	-7.04%	-6.30%	51.44	5.93	3.42%	23.09%
BAX	20.6B	14.8B	-4.91%	-14.77%	7.77	1.39	2.12%	209.17%
MID-CAP
ATR	9.5B	3.5B	1.73%	23.52%	30.36	2.68	6.16%	35.06%
HSIC	9.4B	12.3B	-3.30%	-9.63%	22.56	0.76	-2.44%	-22.68%
BIO	8.1B	2.7B	-19.88%	-38.53%	-12.7	3.03	-4.68%	82.43%
XRAY	6.4B	4.0B	-7.53%	-26.81%	-47.32	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-2.96%	16.48%	-560.62	9.29	33.86%	89.83%
PDCO	2.3B	6.6B	-5.97%	-4.09%	12.04	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.99%	-14.73%	-1.99	0.42	7.73%	-1066.14%
ANIK	379.2M	166.7M	2.24%	1.21%	-4.59	2.28	6.67%	-456.34%
ANGO	233.1M	324.0M	-0.85%	-30.05%	-1.21	0.72	-3.19%	-337.41%
APYX	48.5M	52.3M	2.94%	-58.82%	-2.59	0.93	17.61%	19.28%
AEMD	3.6M	3.7M	-18.45%	260.53%	-0.29	0.96	5.77%	8.23%

Heart Test Laboratories, Inc. News

Latest updates

Heart Test Laboratories, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)											(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Revenue	276.9%	15.00	4.00	-	2.00	-	3.00	4.00	3.00	-	7.00	-
Cost Of Revenue	200.1%	5.00	2.00	-	760*	-	2.00	1.00	854*	-	6.00	-
Gross Profit	326.0%	10.00	2.00	-	1.00	-	1.00	3.00	2.00	-	2.00	-
Operating Expenses	-2.3%	1,536	1,572	1,599	1,310	1,775	1,431	1,981	1,102	957	676	-
S&GA Expenses	25.9%	1,026	815	1,064	667	926	997	625	403	411	275	-
R&D Expenses	-32.7%	510	757	534	643	849	434	1,356	699	546	401	-
Interest Expenses	-33.6%	118	178	34.00	33.00	33.00	144	77.00	139	78.00	78.00	-
Net Income	6.0%	-1,643	-1,748	-1,632	-1,342	-1,806	-1,573	-2,053	-1,238	-1,034	-501	-
Net Income Margin	70.1%	-311.02*	-1.04	-1.23	-728.58*	-661.26*	-584.77*	-335.93*	-142.73*	-122.68*	-107.57*	-95.77*
Free Cashflow	-117.2%	-2,150	-990	-1,869	-1,023	-1,080	-1,818	-1,192	-966	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet									(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2021Q2
Assets	356.0%	10,801	2,368	2,598	3,287	3,480	4,771	5,567	2,089	1,927
Current Assets	379.6%	8,691	1,812	2,029	2,697	2,870	4,127	5,436	1,931	1,638
Cash Equivalents	6966.3%	7,076	100	576	1,660	1,931	3,076	4,078	918	723
Inventory	-0.7%	670	675	676	676	677	678	678	674	751
Net PPE	9.5%	58.00	53.00	59.00	61.00	61.00	64.00	71.00	70.00	95.00
Liabilities	-46.1%	2,167	4,018	3,118	3,057	3,738	3,688	2,680	8,145	3,837
Current Liabilities	-51.7%	1,706	3,531	1,898	1,833	1,985	3,139	1,542	3,471	1,114
Shareholder's Equity	623.4%	8,634	-1,649	-	231	-257	1,083	2,887	-6,055	-
Retained Earnings	-2.6%	-65,516	-63,872	-62,100	-60,800	-59,124	-57,800	-56,000	-54,400	-49,574
Additional Paid-In Capital	19.1%	74,086	62,211	61,593	60,977	58,858	58,857	58,855	48,343	47,661
Shares Outstanding	467.3%	63,612	11,213	10,671	10,118	7,372	8,210	5,645	3,324	3,314

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)												(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Cashflow From Operations	-116.7%	-2,141	-988	-1,404	-1,861	-1,020	-1,080	-1,811	-1,192	-966	-768	-717	-
Share Based Compensation	-9.2%	96.00	106	125	99.00	2.00	2.00	146	-49.85	116	834*	2.00	-
Cashflow From Investing	-350.5%	-8.79	-1.95	-4.91	-7.59	-3.47	-	-7.25	-	-	-	-	-
Cashflow From Financing	1673.4%	9,127	515	324	1,599	-121	-116	5,173	782	1,924	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HSCS Income Statement

2024-01-31

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
Income Statement [Abstract]
Revenue	$ 14,700	$ 1,950	$ 18,600	$ 5,150
Cost of sales	4,561	760	6,081	2,796
Gross margin	10,139	1,190	12,519	2,354
Operating expenses:
Research and development	509,507	643,258	1,832,442	1,926,432
Selling, general and administrative	1,026,014	667,235	2,606,057	2,590,227
Total operating expenses	1,535,521	1,310,493	4,438,499	4,516,659
Loss from operations	(1,525,382)	(1,309,303)	(4,425,980)	(4,514,305)
Other income (expense)
Interest expense	(118,445)	(32,805)	(333,143)	(209,217)
Other expense		(7)
Other income	16	0	79	1,593
Total other (expense) income	(118,429)	(32,812)	(333,064)	(207,624)
Net loss	$ (1,643,811)	$ (1,342,115)	$ (4,759,044)	$ (4,721,929)
Net loss per share, basic	$ (0.03)	$ (0.16)	$ (0.19)	$ (0.64)
Net loss per share, diluted	$ (0.03)	$ (0.16)	$ (0.19)	$ (0.64)
Weighted average common shares outstanding, basic	53,792,741	8,240,798	25,201,024	7,371,764
Weighted average common shares outstanding, diluted	53,792,741	8,240,798	25,201,024	7,371,764

HSCS Balance Sheet

2024-01-31

Condensed Balance Sheets - USD ($)	Jan. 31, 2024	Apr. 30, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 7,076,497	$ 1,660,467
Accounts receivable	14,700
Inventory	670,278	676,359
Prepaid expenses	233,322	143,460
Other current assets	40,374	40,374
Deferred offering costs	655,579	175,921
Total current assets	8,690,750	2,696,581
Property and equipment, net	58,393	61,428
Intangible assets, net	1,568,818
Right-of-use assets, net	482,743	529,224
TOTAL ASSETS	10,800,704	3,287,233
CURRENT LIABILITIES
Accounts payable	415,076	631,369
Accrued expenses	584,427	623,391
Operating lease liabilities, current	98,319	29,535
Current portion of notes payable	500,000	500,000
Other current liabilities	108,187	48,596
Total current liabilities	1,706,009	1,832,891
LONG-TERM LIABILITIES
Notes payable		500,000
Accrued expenses		187,450
Operating lease liabilities, long-term portion	460,859	536,335
Total long-term liabilities	460,859	1,223,785
TOTAL LIABILITIES	2,166,868	3,056,676
COMMITMENTS AND CONTINGENCIES (NOTE 2, 5, and 8)
STOCKHOLDERS' EQUITY
Common Stock, $0.001 par value, 500,000,000 shares authorized; 63,611,630 shares issued and outstanding as of January 31, 2024 and 10,118,440 shares issued and outstanding as of April 30, 2023.	63,611	10,118
Additional paid-in capital	74,086,087	60,977,256
Accumulated deficit	(65,516,242)	(60,757,198)
TOTAL STOCKHOLDERS' EQUITY	8,633,836	230,557
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	10,800,704	3,287,233
Series A, B and C Convertible Preferred Stock
STOCKHOLDERS' EQUITY
Series A, B, and C convertible preferred stock, $0.001 par value, 20,000,000 shares authorized and 620,000 designated; 380,440 shares issued and outstanding as of January 31, 2024 and 380,871 shares issued and outstanding as of April 30, 2023.	$ 380	$ 381

About Heart Test Laboratories, Inc.

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

CEO	Mr. Andrew Simpson
WEBSITE	https://heartsciences.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	12

Heart Test Laboratories, Inc. Frequently Asked Questions

What is the ticker symbol for Heart Test Laboratories, Inc.? What does HSCS stand for in stocks?

HSCS is the stock ticker symbol of Heart Test Laboratories, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Heart Test Laboratories, Inc. (HSCS)?

As of Mon Apr 29 2024, market cap of Heart Test Laboratories, Inc. is 6.56 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HSCS stock?

You can check HSCS's fair value in chart for subscribers.

What is the fair value of HSCS stock?

You can check HSCS's fair value in chart for subscribers. The fair value of Heart Test Laboratories, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Heart Test Laboratories, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HSCS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Heart Test Laboratories, Inc. a good stock to buy?

The fair value guage provides a quick view whether HSCS is over valued or under valued. Whether Heart Test Laboratories, Inc. is cheap or expensive depends on the assumptions which impact Heart Test Laboratories, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HSCS.

What is Heart Test Laboratories, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, HSCS's PE ratio (Price to Earnings) is -1.03 and Price to Sales (PS) ratio is 319.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HSCS PE ratio will change depending on the future growth rate expectations of investors.